BPOM Achieves WHO Listed Authority Status: What Benefits for Indonesian Vaccine Manufacturers?
Jakarta, CNBC Indonesia — CNBC Indonesia held a Health Forum with the theme “BPOM Achieves WHO Listed Authority Status: What Benefits for Business Operators?” which thoroughly examined the impact of Indonesia’s Food and Drug Authority (BPOM) gaining recognition from the world health body and being added to the WHO Listed Authority (WLA) register.
The Deputy of Drug Supervision, Narcotics, Psychotropic Substances, Precursors and Addictive Substances at BPOM, William Adi Teja stated that BPOM attained WLA status thanks to successfully meeting nine criteria established by the WHO, including efficiency and integrity in evaluating pharmaceutical products and vaccines imported into Indonesia, which now matches developed nations.
BPOM will continue to maintain and preserve WLA status, which is reviewed every five years. From the business perspective, BPOM’s success was described by Bio Farma’s Chief Executive Officer, Shadiq Akasya as recognition from the world of the equivalence of Indonesian product quality with global products. This will also drive efficiency and facilitate the development and export of Indonesian pharmaceutical products.
For vaccine producers, BPOM’s achievement was described by Biotis Pharmaceuticals Indonesia’s Chief Executive Officer, FX Sudirman as supporting domestic vaccine development, particularly regarding the credibility of Indonesian products being on par with developed nations.
On the other hand, PT Etana Biotechnologies Indonesia’s Director of Corporate Relations and Strategic Affairs, Andreas Donny Prakasa noted that the elevation of BPOM’s status has significant implications for the biopharmaceutical industry as it can boost confidence levels among pharmaceutical and vaccine manufacturers whilst enhancing the competitiveness of Indonesian products.
The Health Forum brought together Deputy of Drug Supervision at BPOM, William Adi Teja, Bio Farma CEO Shadiq Akasya, Biotis Pharmaceuticals Indonesia CEO FX Sudirman and PT Etana Biotechnologies Indonesia’s Andreas Donny Prakasa for discussion moderated by Shafinaz Nachiar on CNBC Indonesia (Friday, 27 February 2026).